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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and 
gamma-linolenic acid (GLA) and contribution to normal cognitive function 
(ID 532) and maintenance of normal bone (ID 642, 697, 1552) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
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European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and gamma-linolenic acid 
(GLA) and contribution to normal cognitive function and maintenance of normal bone. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food constituents that are the subjects of the health claims are “omega-3 and omega-6 fatty acids 
(GLA)”, “gamma-linolenic acid + eicosapentaenoic acid (GLA+EPA)”, and “evening primrose oil 
and fish oil”. From the references provided, the Panel assumes that the food constituents that are the 
subject of the claims are the n-6 fatty acid gamma-linolenic acid (GLA) in evening primrose oil and 
the n-3 long-chain polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic 
acid (EPA) in fish oil. The Panel considers that the food constituents, DHA, EPA and GLA, are 
sufficiently characterised. 
Contribution to normal cognitive function 
The claimed effect is “brain function (adult & children)”. The Panel assumes that the target 
population is the general population. In the context of the clarifications provided by Member States, 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1319, EFSA-Q-2008-1429, EFSA-Q-2008-1484, 
EFSA-Q-2008-2289, adopted on 25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 
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the Panel assumes that the claimed effect refers to the contribution to normal cognitive function. The 
Panel considers that contribution to normal cognitive function is a beneficial physiological effect. 
No human studies have been provided on the effect of the consumption of a combination of DHA, 
EPA and GLA on cognitive endpoints. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of DHA, EPA and GLA and contribution to normal 
cognitive function. 
Maintenance of normal bone 
The claimed effect is “bone health”. The Panel assumes that the target population is the general 
population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers 
to the maintenance of normal bone through the promotion of calcium absorption. The Panel considers 
that maintenance of normal bone is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that two of the human intervention studies from 
which conclusions could be drawn for the scientific substantiation of the claim did not show an effect 
of the food constituents on bone mineral density, that in a third study acute changes in markers of 
bone turnover did not predict the occurrence of an effect on bone mineral density and/or mass, and 
that evidence provided in animal and in vitro studies is not sufficient to predict the occurrence of an 
effect of the consumption of DHA, EPA and GLA on the maintenance of bone in vivo in humans. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of DHA, EPA and GLA and maintenance of normal bone. 
KEY WORDS 
Docosahexaenoic acid, eicosapentaenoic acid, gamma-linolenic acid, DHA, EPA, GLA, cognitive function, bone 
mineral density, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituents that are the subjects of the health claims are “omega-3 and omega-6 fatty acids 
(GLA)”, “gamma-linolenic acid + eicosapentaenoic acid (GLA+EPA)”, and “evening primrose oil 
and fish oil”. 
Evening primrose oil and fish oil are not sufficiently defined in the information provided with respect 
to manufacturing process or fatty acid composition. From the references provided, the Panel assumes 
that the food constituents that are the subject of the health claims are the n-6 fatty acid gamma-
linolenic acid (GLA) in evening primrose oil and the n-3 long-chain polyunsaturated fatty acids 
(LC-PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in fish oil. 
The n-3 LC-PUFAs, DHA and EPA, are well recognised nutrients which are measurable in foods by 
established methods. They are well absorbed when consumed in the form of triglycerides. 
GLA is an n-6 LC-PUFA which is present in small amounts in a variety of foods of both plant and 
animal origin, and which can also be synthesised in the human body from its precursor linoleic acid 
(LA). GLA is a well recognised nutrient and can be measured in foods by established methods. 
The Panel considers that the food constituents, DHA, EPA and GLA, which are the subject of the 
health claims, are sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Contribution to normal cognitive function (ID 532) 
The claimed effect is “brain function (adult & children)”. The Panel assumes that the target 
population is the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to contribution to normal cognitive function. Cognitive function includes memory, 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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attention (concentration), learning, intelligence and problem solving, which are well defined 
constructs and which can be measured by validated psychometric cognitive tests. 
The Panel considers that contribution to normal cognitive function is a beneficial physiological effect. 
2.2. Maintenance of normal bone (ID 642, 697, 1552) 
The claimed effect is “bone health”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
maintenance of normal bone through the promotion of calcium absorption. 
The Panel considers that maintenance of normal bone is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
3.1. Contribution to normal cognitive function (ID 532) 
The references provided to substantiate the claim included narrative reviews on the role of n-3 and n-6 
fatty acids in the brain which did not provide original data for the scientific substantiation of the 
claim. One study investigated correlations between nutrient intake and the lipid profiles of meibomian 
gland secretions in women with Sjögren's syndrome. Three studies addressed the effects of food 
constituents other than DHA, EPA and GLA on cognitive-related outcomes (i.e. DHA and arachidonic 
acid, total n-3 fatty acids). One animal study investigated the effect of an n-3 fatty acid-depleted diet 
on the brain, retina, and liver fatty acyl composition of rats. The Panel considers that no conclusions 
can be drawn from these references for the scientific substantiation of the claim. 
The Panel notes that no human studies have been provided on the effect of the consumption of a 
combination of DHA, EPA and GLA on cognitive endpoints. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of DHA, EPA and GLA and contribution to normal cognitive function. 
3.2. Maintenance of normal bone (ID 642, 697, 1552) 
A number of narrative reviews on the effects of dietary fats and fatty acids on calcium absorption and 
excretion, and on bone mass and bone turnover in different population subgroups, which included no 
original data that could be used for the scientific substantiation of the claim, and human intervention 
studies on the effects of different fats and combinations of fatty acids on health outcomes (e.g. 
urolithiasis, calcium absorption, and fatty acid profiles in blood and cells) other than the claimed 
effect, were provided. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim. 
In a pilot randomised controlled intervention (Kruger et al., 1998), 66 elderly women (mean age 
79.5 years) living in nursing homes, and with a clinical diagnosis of osteopenia or osteoporosis, were 
assigned to consume 6 g of a mixture of evening primrose oil and fish oil (60 % linoleic acid (LA), 
8 % GLA, 4 % EPA and 3 % DHA) or 6 g of a control oil (coconut oil, 97 % saturated fatty acids, 
0.2 % LA) for 18 months. A total of 21 women consumed the evening primrose and fish oil mixture 
for an additional 18 months, irrespective of the study group to which they were randomised. All 
women received 600 mg of calcium carbonate daily. The Panel notes that the follow-up is an open 
label, uncontrolled phase of the study, and considers that no conclusions can be drawn from this 
DHA, EPA and GLA related health claims 
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follow-up for the scientific substantiation of the claim. The oils were supplied in 500 mg capsules, 
and four capsules were consumed three times daily. Bone mineral density (BMD), markers of bone 
turnover, and plasma and urinary calcium, potassium, creatinine and phosphate were assessed at 
baseline, and at 6, 12 and 18 months. No significant differences in any of these variables were 
observed between the intervention and control groups during the study. The Panel notes that this study 
does not show an effect of the food constituents on the maintenance of bone. 
Bassey et al. (2000) reported on one RCT in which 43 pre-menopausal women (age range 
25-40 years) and 42 post-menopausal women (age range 50-65 years) were randomly assigned to 
consume capsules (10 daily) each providing 4 g of evening primrose oil and 440 mg of marine fish oil 
plus one gram of calcium, or one gram of calcium only (control), for 12 months. The Panel assumes 
that the composition of the evening primrose oil plus marine fish oil mixture is the same as in the 
study by Kruger et al. (1998). Randomisation and data analysis were performed separately for pre- 
and post-menopausal women. BMD (primary outcome) and markers of bone turnover were assessed at 
the beginning and end of the study. No significant differences between intervention and control 
groups were observed with respect to any of these variables during the study. The Panel notes that this 
study does not show an effect of the food constituents on the maintenance of bone. 
A randomised controlled intervention study on the effects of evening primrose oil, fish oil, a mixture 
of evening primrose and fish oil, and olive oil (placebo) given for 16 weeks on calcium absorption 
and excretion, and on markers of bone turnover, was provided (van Papendorp et al., 1995). BMD was 
not assessed in this study. The Panel notes that acute changes in markers of bone turnover do not 
predict the occurrence of an effect on bone mineral density and/or mass, and considers that no 
conclusions can be drawn from this study for the scientific substantiation of the claim. 
Several studies on the effects of different fats and fatty acids on bone loss, bone mass, BMD and bone 
turnover in different animal models of post-menopausal osteoporosis (e.g. ovariectomised rats), and a 
series of in vitro studies which used osteoblast/osteoclast cell lines, were provided. The Panel 
considers that evidence provided in animal and in vitro studies is not sufficient to predict the 
occurrence of an effect of the consumption of DHA, EPA and GLA on the maintenance of bone 
in vivo in humans. 
In weighing the evidence, the Panel took into account that two of the human intervention studies from 
which conclusions could be drawn for the scientific substantiation of the claim did not show an effect 
of the food constituents on bone mineral density, that in a third study acute changes in markers of 
bone turnover do not predict the occurrence of an effect on bone mineral density and/or mass, and that 
evidence provided in animal and in vitro studies is not sufficient to predict the occurrence of an effect 
of the consumption of DHA, EPA and GLA on the maintenance of bone in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of DHA, EPA and GLA and maintenance of normal bone. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituents, DHA, EPA and GLA, which are the subject of the health claims, are 
sufficiently characterised. 
Contribution to normal cognitive function (ID 532) 
 The claimed effect is “brain function (adult & children)”. The target population is assumed to 
be the general population. In the context of the clarifications provided by Member States, it is 
DHA, EPA and GLA related health claims 
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assumed that the claimed effect refers to contribution to normal cognitive function. 
Contribution to normal cognitive function is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of DHA, 
EPA and GLA and contribution to normal cognitive function. 
Maintenance of normal bone (ID 642, 697, 1552) 
 The claimed effect is “bone health”. The target population is assumed to be the general 
population. In the context of the proposed wordings, it is assumed that the claimed effect 
refers to the maintenance of normal bone through the promotion of calcium absorption. 
Maintenance of normal bone is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of DHA, 
EPA and GLA and maintenance of normal bone. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1319, 
EFSA-Q-2008-1429, EFSA-Q-2008-1484, EFSA-Q-2008-2289). The scientific substantiation is based 
on the information provided by the Member States in the consolidated list of Article 13 health claims 
and references that EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES 
Bassey EJ, Littlewood JJ, Rothwell MC and Pye DW, 2000. Lack of effect of supplementation with 
essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two 
randomized controlled trials of Efacal v. calcium alone. British Journal of Nutrition, 83, 629-635. 
Kruger MC, Coetzer H, de Winter R, Gericke G and van Papendorp DH, 1998. Calcium, gamma-
linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging, 10, 385-
394. 
Van Papendorp DH, Coetzer H and Kruger MC, 1995. Biochemical profile of osteoporotic patients on 
essential fatty acid supplementation. Nutrition Research, 15, 325-334. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
DHA, EPA and GLA related health claims 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
DHA, EPA and GLA related health claims 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
DHA, EPA and GLA related health claims 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to DHA, EPA and GLA, including conditions of use from 
similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
532 Omega-3 and Omega-6 fatty 
acids (GLA) 
Brain Function (Adult & 
Children) 
Clarification provided 
Brain Function - Omega-3 
and Omega-6 Fatty Acids 
help cognitive functions such 
as working memory and 
focus, learning ability and 
reading ability 
Omega 3 & 6 supports 
cognitive/brain function 
Conditions of use 
- Yes Richtiges Verhältnis von omega-3 und omega-6 Fettsäuren zugunsten der omega-3 
Fettsäuren 
- 100-3000mg EPA+DHA per day 
ID Food or Food constituent Health Relationship Proposed wording 
642 Gamma-linolenic acid + 
eicosapentaenoic acid 
(GLA+EPA) 
Bone health Helps to maintain strong 
bones  
contributes to the maintenance 
of normal bone strength in 
post-menopausal women  
contributes to the maintenance 
of normal bone strength in the 
elderly  
GLA with EPA help to 
preserve bone density 
Conditions of use 
- 320-480 mg GLA/day (current knowledge: GLA/EPA ratio lower or equal to 3/1) 
ID Food or Food constituent Health Relationship Proposed wording 
697 Evening primrose oil and fish 
oil 
Bone health Helps maintain bone 
strength/helps maintain bone 
density and strength by 
increasing intestinal calcium 
absorption and reducing 
urinary calcium excretion 
Conditions of use 
- Product-specific claim: 4-6 g of 80 % EPO and 20 % FO per day 
ID Food or Food constituent Health Relationship Proposed wording 




helps maintain bone density 
and strength by increasing 
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intestinal calcium absorption 
Conditions of use 
- Produktspezifische Auslobung: 4-6 g of 80 % EPO und 20 % FO pro Tag 
- Product-specific claim: 4-6 g of 80 % EPO and 20 % FO per day 
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GLOSSARY AND ABBREVIATIONS 
BMD  Bone mineral density 
DHA  Docosahexaenoic acid 
EPA  Eicosapentaenoic acid 
GLA  Gamma-linolenic acid 
LA  Linoleic acid 
LCPUFA Long-chain polyunsaturated fatty acid 
RCT  Randomised controlled trial 
